TTK Healthcare Past Earnings Performance
Past criteria checks 5/6
TTK Healthcare has been growing earnings at an average annual rate of 21.6%, while the Pharmaceuticals industry saw earnings growing at 14.8% annually. Revenues have been growing at an average rate of 4.1% per year. TTK Healthcare's return on equity is 6.7%, and it has net margins of 8.6%.
Key information
21.6%
Earnings growth rate
22.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 4.1% |
| Return on equity | 6.7% |
| Net Margin | 8.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How TTK Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 7,519 | 650 | 2,321 | 0 |
| 30 Sep 23 | 7,506 | 641 | 2,320 | 0 |
| 30 Jun 23 | 7,346 | 560 | 2,295 | 0 |
| 31 Mar 23 | 7,251 | 447 | 2,272 | 0 |
| 31 Dec 22 | 7,036 | 285 | 2,186 | 0 |
| 30 Sep 22 | 6,798 | 226 | 2,116 | 0 |
| 30 Jun 22 | 6,605 | 185 | 2,031 | 0 |
| 31 Mar 22 | 5,992 | 185 | 1,954 | 0 |
| 31 Dec 21 | 7,709 | 413 | 2,498 | 0 |
| 30 Sep 21 | 7,376 | 368 | 2,468 | 0 |
| 30 Jun 21 | 6,909 | 548 | 2,483 | 0 |
| 31 Mar 21 | 4,761 | 368 | 1,659 | 0 |
| 31 Dec 20 | 5,918 | 365 | 2,392 | 0 |
| 30 Sep 20 | 5,784 | 333 | 2,353 | 0 |
| 30 Jun 20 | 5,836 | 63 | 1,421 | 0 |
| 31 Mar 20 | 6,458 | 123 | 2,355 | 0 |
| 31 Dec 19 | 6,489 | 169 | 1,447 | 0 |
| 30 Sep 19 | 6,321 | 173 | 1,389 | 0 |
| 30 Jun 19 | 6,333 | 201 | 1,344 | 0 |
| 31 Mar 19 | 6,279 | 244 | 1,308 | 0 |
| 31 Dec 18 | 6,334 | 274 | 2,013 | 0 |
| 30 Sep 18 | 6,313 | 348 | 1,920 | 0 |
| 30 Jun 18 | 6,207 | 393 | 1,895 | 0 |
| 31 Mar 18 | 5,775 | 182 | 1,889 | 0 |
| 31 Dec 17 | 5,541 | 158 | 1,767 | 0 |
| 30 Sep 17 | 5,126 | 126 | 1,616 | 0 |
| 30 Jun 17 | 5,054 | 93 | 893 | 0 |
| 31 Mar 17 | 5,278 | 187 | 1,543 | 0 |
| 31 Dec 16 | 5,360 | 197 | 1,629 | 0 |
| 30 Sep 16 | 5,399 | 234 | 1,646 | 0 |
| 30 Jun 16 | 5,334 | 236 | 1,634 | 0 |
| 31 Mar 16 | 5,189 | 227 | 1,606 | 0 |
| 31 Dec 15 | 5,079 | 213 | 2,243 | 0 |
| 30 Sep 15 | 5,012 | 182 | 2,228 | 0 |
| 30 Jun 15 | 4,918 | 173 | 2,209 | 0 |
| 31 Mar 15 | 4,829 | 162 | 1,539 | 0 |
| 31 Dec 14 | 4,716 | 148 | 2,101 | 0 |
| 30 Sep 14 | 4,565 | 141 | 2,038 | 0 |
| 30 Jun 14 | 4,368 | 140 | 1,949 | 0 |
| 31 Mar 14 | 4,162 | 124 | 1,872 | 0 |
| 31 Dec 13 | 4,016 | 114 | 1,714 | 0 |
| 30 Sep 13 | 3,881 | 110 | 1,668 | 0 |
| 30 Jun 13 | 3,829 | 114 | 1,632 | 0 |
Quality Earnings: 507747 has high quality earnings.
Growing Profit Margin: 507747's current net profit margins (8.6%) are higher than last year (4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 507747's earnings have grown significantly by 21.6% per year over the past 5 years.
Accelerating Growth: 507747's earnings growth over the past year (128.3%) exceeds its 5-year average (21.6% per year).
Earnings vs Industry: 507747 earnings growth over the past year (128.3%) exceeded the Pharmaceuticals industry 23.8%.
Return on Equity
High ROE: 507747's Return on Equity (6.7%) is considered low.